slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol PowerPoint Presentation
Download Presentation
Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol

Loading in 2 Seconds...

play fullscreen
1 / 1

Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol - PowerPoint PPT Presentation

  • Uploaded on

Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol . 4 / 11 / 12. Robert F. Sidonio, Jr. MD, MSc . . Enoxaparin Dosing Goal anti- Xa levels are 0.6 – 1 units/ mL.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol' - delora

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol


Robert F. Sidonio, Jr. MD, MSc.

  • Enoxaparin
  • Dosing
  • Goal anti-Xa levels are 0.6 – 1 units/mL.
  • Certain patient populations (i.e. pregnancy, Berlin heart, etc.) may require higher anti-Xa levels. The pharmacist should be contacted if higher anti-Xa levels are needed in these patients.
  • Doses to achieve therapeutic anticoagulation are highest in infants because of altered heparin pharmacokinetics, larger volume of distribution and physiologically low antithrombin activity.
  • Consider additional monitoring at least once during acute illness requiring hospitalization, all inpatient cardiac patients and any acute renal impairment.
  • Monitoring once at admission and again weekly is a reasonable monitoring plan while hospitalized for illness.
  • Enoxaparin Dosing
  • Monitoring and Considerations
  • Administration is via injection into subcutaneous tissue.
  • Consider topical lidocaine or EMLA cream 20 minutes prior to dosing to reduce discomfort in children.
  • Monitoring should begin after the second dose is administered.
  • Check an anti-Factor Xa level 4-5 hours after an AM dose. Dosing will be given at 0800/2000 while inpatient to ensure appropriate lab turnaround time.
  • Please consult the Pharmacy Enoxaparin monitoring service for help in dosage adjustment while inpatient.
  • Pharmacy enoxaparin monitoring service will be paged when new orders for enoxaparin are ordered in WIZ/HEO. The anticoagulation dashboard will also be utilized.
  • If patient is sent home on enoxaparin then consult Pediatric Hematology thrombosis nurse for parent education in administration.
  • If patient is transitioned to generic enoxaparin, patients will have anti-Xa level drawn initially to ensure no deviation. Levels will then be followed via nomogram.
  • Administration with an Insuflon catheter should be avoided since difficult to obtain outpatient
  • Dosage titration nomogram
  • For patients < 10 kg, all doses will be rounded to the nearest 0.5 milligram to aid in ease of dosing administration upon discharge. For patients ≥ 10 kg, doses will be rounded to the nearest whole milligram.
  • Conversion from UFH to Enoxaparin
  • Give 1st dose of Enoxparin at the same time the UFH drip is stopped.
  • Conversion from Enoxaparin to UFH
  • If > 12 hours since last enoxaparin dose, give standard bolus followed by maintenance continuous UFH drip.
  • If 8-12 hours since last enoxaparin dose, give only the standard maintenance continuous UFH drip, skipping the bolus.
  • Procedures
  • For cardiac catheterization hold only the AM dose prior to procedure.
  • For invasive or surgical procedures hold a total of two doses thus the PM dose and the AM dose.
  • Restarting enoxaparin is per discretion of the surgeon or cardiologist, typically within 12-24 hours.
  • Heparin
  • Dosing and monitoring
  • Obtain a baseline CBC, PT, aPTT, Fibrinogen and correct coagulopathies as needed.
  • Initial Loading dose: 75 Units/kg over 10 minutes (Maximum 5000 units)
  • Initial Maintenance dose
  • Infusion begins after initial bolus is complete
    • < 1 year: 28 units/kg/hr
    • ≥ 1 year: 20 units/kg/hr (Maximum initial rate 1000 units/hour)
  • Obtain blood for aPTT 4 hours after loading dose and adjust based on nomogram below.
  • Follow adjustment guidelines below to maintain aPTT between 65 – 100 seconds (assuming this reflects anti-factor Xa of 0.35 – 0.7 units/mL)
  • Patients with prolonged baseline aPTT, infants, perceived difficulty managing therapeutic aPTT, excessive bleeding with therapeutic aPTT, or progression of thrombus with therapeutic aPTTmay be monitored predominantly with anti-Factor Xa levels but encourage daily PTT (drawn at same time as anti-FXa) surveillance. Please discuss with hematology service.
  • Please page the clinical pharmacist on the patient’s service when planning transition to enoxaparin or warfarin.
  • Obtain blood for aPTT/anti-FXa 4 hours after each dose adjustment and readjust as needed.
  • Maintain fibrinogen >100 mg/dL and platelet count >50k while on UFH.
  • When aPTT/anti-FXa is therapeutic on 2 consecutive samples, obtain blood for CBC, aPTT and anti-FXa level daily x 5 days.
  • Thereafter can check CBC every other day or twice a week if limited blood draws are needed.
  • Discrepancies may arise between anti-FXa and aPTT. Use clinical judgement, would recommend utilizing anti-FXa as it correlates more closely with Heparin levels.
  • Reversal of Enoxaparin
  • There is no proven method for neutralizing LMWH and protamine leads to incomplete reversal.
  • Consultation with hematology is recommended prior to administration.
  • Protamine is rarely indicated as the preferred strategy over observation.
  • If LMWH was given within 8 hours, protamine sulfate should be administered in a dose of 1 mg per 100 anti-Xa units of LMWH (maximum dose 50 mg). 1 mg enoxaparin equals approximately 100 anti-Xaunits.
  • A second dose of 0.5 mg protamine sulfate per 100 anti-Xa units should be administered if bleeding continues.